曲妥珠单抗联合新辅助化疗对乳腺癌患者术后临床疗效及相关指标的影响

发布时间：2018-06-02 01:08

本文选题：乳腺癌 + 曲妥珠单抗　；参考：《中国药房》2017年11期

【摘要】：目的:探讨曲妥珠单抗联合新辅助化疗对乳腺癌患者术后临床疗效及血清中血管新生因子、乳腺组织中凋亡分子的影响。方法:选择2012年1月-2014年12年在我院接受住院治疗的乳腺癌患者116例作为研究对象,按照随机数表法分为对照组和观察组,各58例。对照组术前给予注射用卡铂100 mg(加入5%葡萄糖注射液稀释至10 mg/m L,再加入500 m L葡萄糖注射液中),于每个化疗周期的第1天ivgtt,200~400 mg/m2;多西他赛注射液于每个化疗周期的第1天ivgtt,75 mg/m2。观察组在对照组基础上加用注射用曲妥珠单抗,第1周剂量4 mg/kg,第2~18周剂量为2 mg/kg,每周1次,ivgtt。3周为1个周期,两组患者均持续治疗6个周期,治疗结束2周后行乳腺癌改良根治术。观察两组患者治疗前后血清血管新生因子水平和乳腺组织凋亡分子水平,并比较两组患者治疗结束后1年时的临床疗效及不良反应发生情况。结果:治疗前,两组患者血清血管新生因子和乳腺组织凋亡分子水平比较,差异均无统计学意义(P0.05);治疗后,两组患者血清血管新生因子和乳腺组织凋亡分子水平显著降低,且观察组显著低于对照组,差异均有统计学意义(P0.05)。观察组患者临床有效率为82.76%,显著高于对照组的56.90%,差异有统计学意义(P0.05)。两组患者不良反应发生率比较,差异无统计学意义(P0.05)。结论:曲妥珠单抗联合新辅助化疗有助于提高乳腺癌治疗效果、防止复发,降低血清中血管新生因子及乳腺组织凋亡分子表达水平,且安全性较好。
[Abstract]:Aim: to investigate the effect of tritozumab combined with neoadjuvant chemotherapy on postoperative clinical efficacy of breast cancer patients and the effect of serum angiogenic factors and apoptosis molecules in breast tissues. Methods: 116 breast cancer patients who were hospitalized in our hospital from January 2012 to 2014 were divided into control group and observation group according to random number table method. The control group was administrated with carboplatin 100mg (5% glucose injection diluted to 10 mg/m / L, then added 500ml glucose injection) before operation, iv GTT 200400 mg / m ~ 2 on the first day of each chemotherapy cycle, and doxetaxel injection was iv gttt 75 mg / m ~ 2 on the first day of each chemotherapy cycle. In the observation group, the dosage of tratuzumab for injection was 4 mg / kg in the first week, 2 mg / kg in the second week 18 weeks, and 1 cycle in the week of iv gtt.3 once a week. The patients in both groups were treated continuously for 6 cycles. Modified radical mastectomy was performed 2 weeks after treatment. The levels of serum angiogenic factors and breast tissue apoptotic molecules were observed before and after treatment, and the clinical efficacy and adverse reactions were compared between the two groups at 1 year after treatment. Results: before treatment, the levels of serum angiogenic factors and breast tissue apoptotic molecules were not significantly different between the two groups, but the levels of serum angiogenic factors and breast tissue apoptotic molecules were significantly decreased after treatment. The observation group was significantly lower than the control group, the difference was statistically significant (P 0.05). The clinical effective rate of the observation group was 82.76, which was significantly higher than that of the control group (56.90). The difference was statistically significant (P 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P 0.05). Conclusion: the combination of trotozumab and neoadjuvant chemotherapy can improve the curative effect of breast cancer, prevent recurrence, decrease the expression level of angiogenic factor and apoptotic molecule in breast tissue, and have good safety.
【作者单位】：中国医科大学航空总医院普外乳腺科;北京大学肿瘤医院肝胆胰外1科;
【分类号】：R737.9

【参考文献】